Irritable bowel syndrome: The role of the intestinal microbiota, pathogenesis and therapeutic targets

Acta Gastro-Enterologica Belgica

Volumn 74, Issue 3, 2011, Pages 375-380

  Dahlqvist, G ^a   Piessevaux, H ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Irritable bowel syndrome; Microbiota; Probiotics

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; CYTOKINE; GALACTOSE OLIGOSACCHARIDE; IMMUNOMODULATING AGENT; PROBIOTIC AGENT;

ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL OVERGROWTH; COLON FLORA; CYTOKINE RELEASE; DIGESTIVE SYSTEM INFLAMMATION; DRUG EFFICACY; ENDOCARDITIS; ENTEROCHROMAFFIN CELL; FUNGEMIA; HUMAN; IMMUNOMODULATION; INTESTINE FLORA; INTESTINE ISCHEMIA; IRRITABLE COLON; LAMINA PROPRIA; MAST CELL; MUCOSA CELL; NEUROTRANSMISSION; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE;

ANTI-BACTERIAL AGENTS; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; METAGENOME; PROBIOTICS;

EID: 80053582389     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. SPILLER R., GARSED K. Postinfectious irritable bowel syndrome. Gastroenterology, 2009, 136: 1979-1988.
2. HEITKEMPER M., CAIN K.C., SHULMAN R., BURR R., POPPE A., JARRETT M. Subtypes of irritable bowel syndrome based on Abdominal Pain/discomfort severity and bowel pattern. Dig. Dis. Sci., 2011, 56: 2050-2058.
3. WANG L.H., FANG X.C., PAN G.Z. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut, 2004, 53: 1096-1101.
4. STEWART G.T. Post-dysenteric colitis. Br. Med. J., 1950, 1: 405-409.
5. HARRY H.X. X. Post-infectious irritable bowel syndrome. World J. Gastroenterol., 2009, 15: 3591-3596.
6. SPENCE M.J., MOSS-MORRIS R. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut, 2007, 56: 1066-2071.
7. GWEE K.A., LEONG Y.L., GRAHAM C. The role of psychological and biological factors in post infective gut dysfunction. Gut, 1999, 44: 400-406.
8. JI S., PARK H., LEE D., SONG Y.K., CHOI J.P., LEE S.I. Post-infectious irritable bowel syndrome in patients with Shigella infection. Journal of gastroenterology and hepatology, 2005, 20: 381-386
9. MORTENSEN P.B., CLAUSEN M.R. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand. J. Gastroenterol., Suppl., 1996, 216: 132-48.
10. GHOSHAL U.C., PARK H., GWEE K.-A. Bugs and irritable bowel syndrome: The good, the bad and the ugly. Journal of gastroenterology and hepatology, 2010, 25: 244-251.
11. GWEE K.-A. Post-infectious irritable bowel syndrome, an inflammationimmunological model with relevance for other IBS and Functional dyspepsia. J. Neurogastroenterol. Motil., 2010, 16: 30-34.
12. DUNLOPS P., JENKINS D., SPILLER R.C. Distinctive clinical, psycholo - gical, and histological features of post infective irritable bowel syndromes. Am. J. Gastroenterol., 2003, 98: 1578-1583.
13. GWEE K.-A., COLLINS S.M., READ N.W., RAJNAKOVA A., DENG Y., GRAHAM J.C., MC KENDRICK M.W., MOOCHHALA S.M. Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome. Gut, 2003, 52: 523-526.
14. SPILLER R., JENKINS D., THORNLEY J., HEBDEN J., WRIGHT T., SKINNER M., NEAL K. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut, 2000, 47: 804-811.
15. STERMER E., LUBEZKY A., POTASMAN I., PASTER E., LAVY A. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clinical Infectious Disease, 2006, 43: 898-901.
16. PIMENTEL M., MORALES W., JEE S.-R., LOW K., HWANG L., POKKUNURI V. et al. Antibiotic Prophylaxis Prevents the Development of a Post-Infectious Phenotype in a New Rat Model of Post-Infectious IBS. Dig. Diseases and Sciences, 2011, 56: 1962-1966.
17. GHOSHAL U.C., RANJAN P. Post-infectious irritable bowel syndrome: The past, the present and the future. Journal of gastroenterology and hepatology, 2011, 26: 94-101.
18. CHANG J. Y., TALLEY N.J. Current and emerging therapies in irritable bowel syndrome from pathophysiology to treatment. Trends in pharma - cological Sciences, 2010, 31: 326-334.
19. QUIGLEY E.M. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies. Gastroenterol. Clin. N. Am., 2011, 40: 207-222.
20. DORÉ J., CORTHIER G. Le microbiote interstinal humain. Gastro - entérologie clinique et biologique, 2010, 34: 7-16.
21. POSSERUD I., STOTZE P-O., BJÖRNSSON E.S., ABRAHAMSSON H., SIMRÉN M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. NeuroGastroenterology Gut, 2001, 56: 802-808.
22. PIMENTEL M., CHOW E.J., LIN H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. J. Gastroenterol., 2000, 95: 3503-3506.
23. PIMENTEL M., CHOW E.J., LIN H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol., 2003, 98: 412-419.
24. CODLING C., O-MAHONY L., SHANAHAN F., QUIGLEY E.M., MARCHESI J.R. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dif. Dis. Sci., 2010, 55: 392-397.
25. SALONEN A., DE VOS W.M., PALVA A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspective. Microbiology, 2010, 156: 3205-3215.
26. RINTTILÄ T., LYRA A., KROGIUS-KURIKKA L., PALVA A. Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects. Gut Pathogens, 2011, 3: 6.
27. TANA C., UMESAKI Y., IMAOKA A., HANDA T., KANAZAWA M., FUKUDO S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil., 2010, 22: 512-519.
28. MALINEN E., RINTTILÄ T., KAJANDER K., MÄTTÖ J., KASSINEN A., KROGIUS L. et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am. J. Gastro - enterol., 2005, 100: 373-82.
29. KERCKHOFFS A.P., BEN-AMOR K., SAMSOM M., VAN DER REST M.E., DE VOGEL J., KNOL J., AKKERMANS L.M. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J. Med. Microbiol., 2011, 60: 236-45.
30. RODRÍGUEZ-FANDINO O., HERNANDEZ-RUIZ J., SCHMULSON M. From Cytokines to Toll-Like Receptors and Beyond - Current Knowledge and Future Research Needs in Irritable Bowel Syndrome. J. Neuro gastro - enterol. Motil., 2010, 16: 364-373.
31. BRINT E., MAC SHARRY J., SHANAHAN F., QUIGLEY E.M. Differential expression of Toll-like receptors (TLRS) in Irritable bowel syndrome (IBS). Gastroenterology, 2009, 136: 67.
32. ROWLAND I., CAPURSO L., COLLINS K., CUMMING J., DELZENNE N., GOULET O. et al. Current level of consensus on probiotic science. Report of an expert meeting-London, 23 November 2009. Gut Microbes., 2010, 1: 436-439.
33. SHERMAN P.M., OSSA J.C., JOHNSON-HENRY K. Unravelling mechanisms of action of probiotics. Nutr. Clin. Pract., 2009, 24: 10-14.
34. DELCENSERIE V., MARTEL D., LAMOUREUX M., AMIOT J., BOUTIN Y., ROY D. Immunomodulatory Effects of Probiotics in the Intestinal Tract. Curr. Issues Mol. Biol., 2008, 10: 37-54.
35. MOAYYEDI P., FORD A.C., TALLEY N.J. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut, 2010, 59: 325-32.
36. ROUSSEAUX C., THURU X., GELOT A., BARNICH N., NEUT C., DUBUQUOY L. et al. P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoïd receptors. Nat. Med., 2007, 13: 35-37.
37. OHLAND C.L., MAC NAUGHTON W.K. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 298: 807-19.
38. PARKES G.C., SANDERSON J.D., WHELAN K. Treating irritable bowel syndrome with probiotics: the evidence. Proceeding of the nutrition society, 2010, 69: 187-194.
39. PIMENTEL M., CHOW E.J., LIN H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol., 2003, 98: 412-419.
40. PERALTA S., COTTONE C., DOVERI T., LUIGI ALMASIO P., CRAXI A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin. World J. Gastroenterol., 2009, 15: 2628-2631
41. PIMENTEL M., LEMBO A., CHEY W.D., ZAKKO S., RINGEL Y., YU J. et al. for the TARGET Study Group. Rifaximin Therapy for Patients with Irritable bowel Syndrome without constipation. N. Engl. J. Med., 2011, 364: 22-32.
42. JOLLEY J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clinical and experimental Gastroenterology, 2011, 4: 43-48.
43. DUNLOP S.P., JENKINS D., NEAL K.R., NAESDAL J., BORGAONKER M., COLLINS S.M., SPILLER R.C. Randomized, doubleblind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment. Pharmacol. Ther., 2003, 18: 77-84.
44. http://www.metahit.eu/index.php?id=360 accessed on September 18th 2011.
45. BUENO L. Therapeutic targets. Gastroenterol. Clin. Biol., 2009, 33: 59-67.
46. SILK D.B.A., DAVIS A., VULEVIC J., TZORTZIS G., GIBSON G.R. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther., 2009, 29: 508-18.
47. GADE J., THORN P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand. J. Prim. Health Care, 1989, 7: 23-6.
48. SINN D.H., SONG J.H., KIM H.J., LEE J.H., SON H.J., CHANG D.K. et al. Therapeutic Effect of Lactobacillus acidophilus -SDC, 2012, 2013 in Patients with Irritable Bowel Syndrome. Digestive diseases and sciences, 2008, 53: 2714-2718.
49. O'MAHONY L., MC CARTHY J., KELLY P., HURLEY G., LUO F., CHEN K. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles Gastro - enterology, 2005, 128: 541-545.
50. KAJANDER K., MYLLYLUOMA E., RAJILIC-STOJANOVIC M., KYRÖNPALO S., RASMUSSEN M., JËRVENPÄÄ S. et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentaty Pharmacology and Therapeutics, 2001, 27: 48-57.
51. AGRAWAL A., HOUGHTON L.A., MORRIS J., REILLY B., GUYONNET D., GOUPIL FEUILLERATS N. et al. Clinical trial: The effects of a fermented milk product containing Bifidobacterium lactis DN- 173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Alimentary Pharmacology and therapeutics, 2008, 29: 104-114.